Myelofibrosis (MF)NCT07863466
MPNdpoint. Single-center, Retrospective, Prospective Study of the Outcome of Patients With Philadelphia-negative Chronic Myeloproliferative Neoplasms
An observational study of Myelofibrosis (MF) and Polycythemia Vera, run by Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico at 1 site in Italy.
Trial summary
Chronic myeloproliferative neoplasms (MPNs) are hematologic disorders of the myeloid lineage characterized by clonal proliferation of hematopoietic stem cells, high risk of thrombotic-hemorrhagic complications, and transformation into secondary acute myeloid leukemia. Read more about this study
- Who is it for?
- Ages 16 years and older
- Conditions the study is for
- Myelofibrosis (MF), Polycythemia Vera, Essential Thrombocythaemia
- How many people
- 1,190 participants
- Where
- 1 siteItaly
- Study dates
- 17 Feb 2025to Jun 2044
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 16 years and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Patients 16 years of age and older, diagnosed with polycythemia vera, essential thrombocythemia, prefibrotic and overt primary myelofibrosis, secondary myelofibrosis, followed at Policlinico Hospital (MIlan, Italy)
Who may be able to join
- Patients 16 years of age and older
- Patients diagnosed with polycythemia vera, essential thrombocythemia, prefibrotic and overt primary myelofibrosis, secondary myelofibrosis (Arber et al, Blood 2022 or earlier but reclassified classifications)
Who cannot join
- Patients with diagnosis other than polycythemia vera, essential thrombocythemia, prefibrotic and overt primary myelofibrosis, secondary myelofibrosis
- Follow up of less than 6 months
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Italy1 site, 1 recruiting
- Recruiting
Ospedale Maggiore Policlinico
Milan
Barbara Mora, +390255033345, barbara.mora@policlinico.mi.it
About this study
Chronic myeloproliferative neoplasms (MPNs) are hematologic disorders of the myeloid lineage characterized by clonal proliferation of hematopoietic stem cells, high risk of thrombotic-hemorrhagic complications, and transformation into secondary acute myeloid leukemia. MPNs include: myelofibrosis, polycythemia vera, and essential thrombocythemia. The low incidence, comparable to that of rare diseases, induces the in-depth study of patients and thus the need to develop a project with databases to collect clinical, biological, and therapeutic information.
- Keywords
- Myelofibrosis, Polycythemia Vera, Essential Thrombocythemia
- Medical subject headings
- Primary Myelofibrosis, Polycythemia Vera, Thrombocythemia, Essential
What is being measured
The primary outcome is the main question the study is designed to answer.
Overall Survival
Measured: 20 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Oct 2026
- Study start17 Feb 2025
- Primary completionJun 2044 (estimated)
- Study completionJun 2044 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Myelofibrosis (MF)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Other
- Enrolment
- 1,190 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07863466
- Sponsor's protocol ID
- ID 5475
- Status last verified
- Sep 2026
- First submitted
- 2 Oct 2026
- Last updated
- 7 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No